However, non-motor symptoms, such as cognitive impairment and autonomic dysfunction, potentially linked to neuroendocrine and metabolic dysfunction, are now widely recognized as important features that extend beyond the loss of dopaminergic neurons [1]
Strong competition from global giants Patent and intellectual property barriers Supply chain and manufacturing scale What This Means for Patients For patients, especially in the future: More affordable weight-loss and diabetes drugs Increased availability of GLP-1 therapies Better treatment outcomes Dr
11, 834840 10.1038/embor.2010.160 [DOI] [PMC free article] [PubMed] [Google Scholar] 23.Karlsson, H.K.R., Ahlsn, M., Zierath, J.R., Wallberg-Henriksson, H
Consent for publication The requirement for informed consent was waived because of the retrospective study design
Relation of elevated heart rate in patients with heart failure with reduced ejection fraction to one-year outcomes and costs